It is clear that antibodies can play a pivotal role in preventing the transmission of HIV-1 and large efforts to identify an effective antibody-based vaccine to quell the epidemic. Shortly after HIV-1 was discovered as the cause of AIDS, the search for epitopes recognized by neutralizing antibodies became the driving strategy for an antibody-based vaccine. Neutralization escape variants were discovered shortly thereafter, and, after almost three decades of investigation, it is now known that autologous neutralizing antibody responses and their selection of neutralization resistant HIV-1 variants can lead to broadly neutralizing antibodies in some infected individuals.
of successful passive immunization experiments in NHP models of HIV infection [(19-41) and discussed below]. The barrier to antibodymediated protection against HIV-1 is not high. It is now clear that only one or few variants (so called transmitted/founder viruses or T/F viruses) are capable of establishing nascent infection across a "transmission bottleneck", which is imposed by the recipient via mechanisms only partially understood. [42] [43] [44] [45] [46] [47] [48] [49] [50] Viewed conversely, it is clear that the majority of variants circulating in the transmitting host lack the qualities needed to transmit. Although the existence of a bottleneck in HIV-1 transmission has been known for a number of years, [42] [43] [44] the advent of single genome analysis (SGA) opened the way to quantification of the number of T/F variants [45] [46] [47] [48] [49] [50] as well as their genotypic and phenotypic properties. 47, [51] [52] [53] [54] [55] [56] [57] In addition to using the CCR5 co-receptor, the initial SGA study showed that T/F variants are characterized by preferential growth in CD4 + T cells [see also (47, 58) ], consistent co-receptor masking, resistance to non-broadly neutralizing monoclonal antibodies, and sensitivity to broadly neutralizing monoclonal antibodies. 45 Earlier transmission studies suggested that T/F variants have shortened V1/V2 loops and reduced N-linked Env glycosylation [59] [60] [61] although it is not clear whether these characteristics are shared among all T/F variants.
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Perhaps the most striking feature of T/F variants is that they are consistently marked by signature amino acid residues IAKN at positions 33, 55, 64, and 88 (HXB2 numbering) in the C1 region of gp120
where A55 and N88 are completely conserved across SIV, SHIV, and HIV-1 T/F variants in both naïve and immune hosts. 57, [62] [63] [64] [65] Currently, connections between T/F variants and humoral immunity are studied mainly in the context of neutralizing epitopes and their structure on the T/F envelope. As with all HIV strains, neutralization sensitivity is rank ordered (i.e. in "Tiers") by standardized neutralizing antibody panels in the TZM-bl assay. 66, 67 Tier 1 viruses express many vulnerable sites, have flexible structures and are subject to neutralization by a wide array of anti-Env antibodies. [68] [69] [70] [71] In contrast, Env trimers on Tier-2/3 viruses are more conformationally constrained, expose relatively few vulnerable sites, and are resistant to neutralization by all but a few potent anti-Env antibodies. [68] [69] [70] [71] It is now thought that T/F variants fall into the Tier-2/3 rankings of neutralization sensitivity. 72, 73 Thus, they likely present a limited number of neutralizing epitopes on a relatively constrained envelope structure.
Emphasis on neutralization profiles stems from the widely held belief that these structures will provide key templates for developing protective HIV-1 vaccines and other prophylactic methods. 9, 10 The reasoning is that neutralizing activity is the only way to "mop up" the few variants that do not fall by the wayside during transmission, resulting in sterilizing protection. This rationale follows from multiple studies showing that neutralizing antibodies (albeit not necessarily by neutralizing activity, see below) impose significant immunological pressure on HIV-1 during the course of infection [72] [73] [74] [75] [76] [77] [78] [79] [80] as well as passive immunization studies in non-human primates (NHP) demonstrating protection against high-dose SHIV challenges via neutralizing antibodies. [19] [20] [21] [23] [24] [25] [26] [27] [28] [29] [30] [31] 33, 34, [36] [37] [38] [39] [40] [41] Despite these strengths, the "neutralization only" approach to an HIV-1 vaccine includes three caveats that have significant practical implications. First, it is based on only one possible mechanism for protection, the direct blocking of viral entry, and assumes the other possible mechanisms are secondary in importance, though mounting evidence suggests that Fc-mediated effector function contributes significantly to protection mediated even by broadly neutralizing antibodies. 29, 30, 81 Second, it focuses selectively on highly mutable Env epitopes that enable a perpetual dance between viral and immunological evolution in the host. It is well-known that early HIV-1 transmission is characterized by an autologous neutralizing antibody response to the T/F virus that rapidly elicits neutralization escape variants. 59, 60 These neutralization escape variants elicit new neutralizing antibodies, setting up a predator-prey cycle (repetitive cycles of neutralization and neutralization escape) after HIV-1 transmission [72] [73] [74] [75] [76] [77] [78] [79] [80] that is a common characteristic of persistent lentiviral infections. 82, 83 Recent structural studies indicate that Env trimers of T/F viruses are largely obscured by a glycan cloud that limit exposure of epitopes recognized by broadly neutralizing antibodies. [84] [85] [86] [87] [88] [89] Although these epitopes are targets of broadly neutralizing antibodies, they can clearly escape even the most potent of these antibodies. [90] [91] [92] [93] Thus, the neutralization only approach focuses on epitopes for which escape mutants remain replication competent, though it is possible that escape comes with a fitness cost.
Theoretically, such a vaccine might select for vaccine-resistant T/F variants on a global population level.
Third, the neutralization only approach does not address the significance of emerging T/F signatures in the HIV-1 envelope amino acid sequence. 57, [62] [63] [64] [65] These signatures may have functional and structural significance in the gp120-gp41 interaction and associated replicative capacity 57 but are not direct targets of potent broadly neutralizing antibodies. 57, 62, 64, 65 As noted above, these signatures emerge in immunologically naïve subjects and are not necessarily driven by immune pressure, although this certainly does not preclude them from being exploited as targets for protective antibody responses. An initial report showed that these T/F sequences are associated with neutralization resistance in a SIV model 62 ; however, subsequent studies showed that these T/F sequences are found on neutralization sensitive SIV that is transmitted in vaccinated NHP. 64, 65 Further studies are required to resolve these differences but it is highly likely that whatever the effect of the T/F sequences it lies outside epitopes recognized by neutralizing antibodies.
Although we strongly support efforts to find an HIV-1 vaccine that elicits potent, broadly neutralizing antibodies, the above concerns led us to develop an alternative hypothesis that we term "the nonsurvivor hypothesis". The non-survivor hypothesis is founded on a statistical problem known as survivor bias, 94, 95 that takes into account immunological "hits" on transmitted HIV-1 that are not survivable by mutation and escape. Survivor bias is best illustrated by classical work on defensive aircraft shielding during World War II. 94, 95 Deep in the throes of war, the mathematician Abraham Wald made a seminal contribution to the war effort by determining how to best shield Allied bombers against enemy anti-aircraft fire. 94 Figure 1 satisfies the first requirement, identification of highly conserved sequences in the Env trimer. It is noted that segmental sequence variation in Env has been known since the early days of the AIDS epidemic 98 and the analysis in Figure 1 is shown for illustration of the problem using only gp120 for simplicity. Figure 1 shows an entropy plot for gp120 determined using com- 
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Neutralization escape is also consistent with the high levels of protein sequence variation in the outer domain regions of gp120 (V1-V5)
harboring most of the epitopes recognized by broadly neutralizing antibodies. [108] [109] [110] Although it is very clear that neutralization escape drives the emergence of broadly neutralizing antibodies, it should be noted that even the most broadly neutralizing monoclonal antibodies often fail to neutralize contemporaneous viruses circulating at the time of detection or isolation [cf. (77)]. Thus, the epitopes recognized by known broadly neutralizing antibodies appear to be uniformly "survivors".
Additional data support the hypothesis that broad neutralizing activity is about survival. There is seemingly paradoxical evidence that HIV-1 envelope domains with highly variable amino acid sequences (i.e. neutralization targets) are actually quite stable at the genetic level.
For example, the nucleotide mutation rate in V1 through V5 env gene regions is approximately three-fold less than in the coding regions of the entire HIV-1 genome, including Env codons outside of these regions. 110 The decreased mutation rate is due to sequence context and secondary structure of template RNA that increases the fidelity of reverse transcription and decreases the activity of a cytidine deaminase. As suggested in, 109, 110 it is possible that the reduced cytidine deaminase activity preserves GG and GA targets that favor the evolution of neutralization escape variants without loss of replication capacity. Overall, it appears that HIV-1 has evolved a stable genetic platform that ensures survival even as Env trimers bend with the winds of broadly neutralizing antibody responses. Put another way, HIV-1 makes it very hard for broadly neutralizing antibodies to push HIV-1 variants toward a lethal genotype. This is supported further by the recent demonstration that the highly conserved glycan site at N88 restricts access of broadly neutralizing antibodies to epitopes at the gp120-gp41 interface, although it is not part of the epitope itself. At this juncture, it is useful to consider the semantics of nonneutralizing antibodies. In the discussion to follow, we consider an antibody to be non-neutralizing if consistently fails to neutralize Tier-1 viruses in any standardized assay format in the absence of complement or effector cells. For example, many antibodies will neutralize in the A3R5 assay, which uses a transformed T cell line, whereas they are inactive in the TZM-bl assay that is based on a HeLa cell line.
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When it is considered that T/F viruses are Tier-2/3 in neutralization susceptibility, this definition sets a low threshold for categorization of an antibody as neutralizing since it also includes Tier-1 viruses that are not transmitted. Against this backdrop, is there evidence that nonneutralizing antibodies against HIV-1 can protect against infection?
The answer is qualified "yes" and it comes from both vaccination and passive immunization studies. 
| ANTIBODY-MEDIATED PROTECTION AGAINST HIV-1: ARE NON-NEUTRALIZING ANTIBODIES PROTECTIVE?

| Vaccination studies in NHP
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In that study, NHP were immunized with inactivated SIV and challenged intravenously with SIV, both reagents were derived using human cell substrates. 122 Control groups also included NHP immu- Fc-mediated effector function will be a major mechanism through which non-neutralizing antibodies exert protection.
With these caveats in mind, Fc-mediated effector functions as well A second report, 141 using the conformationally constrained gp120
immunogen, full-length single chain (FLSC), 154 elicited sterilizing heterologous protection against SHIV162p3 in two independent repeat, low-dose challenge studies as well as against a neutralization resistant swarm of SIVmac251 155 in a third repeat, low-dose challenge study.
Protection correlated with antibody specificity for highly conserved CD4-induced epitopes (CD4i) of gp120 (measured in the SHIV162p3 studies) as well ADCC measured in all studies using the rapid fluorometric antibody-dependent cellular cytotoxicity assay (RFADCC). 156 These studies used a gp120 derived from the HIV-1 BA-L isolate that is stabilized in the CD4-bound conformation it elicits CD4i antibodies to the co-receptor binding site and Epitope Cluster A 157 in the C1/C2 region of gp120 for which we have the epitope footprints at the atomic level, [158] [159] [160] [161] [162] which permits that survivor analysis that will be discussed in a section below.
| Vaccination studies in humans
Subgroup studies of the Vax004 trial, which tested a gp120-based vaccine concept, suggested that Fc-mediated ADCVI correlated inversely with infection risk [as defined (163) in and referred to hereafter as correlate of risk (CoR))]. This relationship indicated that non-neutralizing antibodies can prevent HIV-1 transmission by Fc-mediated effector function, 164 although there was no overall efficacy in the trial. 165 In contrast, the RV144 trial was the first HIV-1 vaccine trial to demonstrate efficacy, 166 which peaked at approximately 60% efficacy in the first 18 months 167 and decaying quickly to background resulting in an overall efficacy of 31.2%. 166 The primary CoR were anti-V1/V2 binding antibodies that correlated inversely with CoR and IgA anti-C1 antibodies that correlated directly with CoR. 168 In secondary analyses, IgA 
| Passive immunization studies in NHP
As pointed out above, vaccine studies can only identify correlates of protection, they cannot establish causality. To do so requires passive immunization with selected antibodies and cognate specificities.
Such studies in NHP have established unequivocally that antibodies which neutralize the challenge stock can protect against highdose SHIV challenges [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] 31, 33, 34, [36] [37] [38] [39] 41 as well as repeat, low-dose SHIV challenges. 30, 35 In contrast, save for one early study using nonneutralizing antibodies against SIV, 177, 178 no other passive immunization study using non-neutralizing antibodies as immune sera 179, 180 or monoclonal antibodies 33, 37, 181 has protected against a high-dose SHIV/SIV challenge. These studies show clearly that neutralizing antibodies, and broadly neutralizing antibodies in particular, have a wide dynamic range for protection against HIV-1. They also show that non-neutralizing antibodies are not effective for blocking SHIV infection at the top end of this range, which is typically around 10 8 copies per challenge. 30 These three studies also provide evidence that nonneutralizing antibodies do impact high-dose SHIV challenges. 33, 37, 181 All three studies included non-neutralizing monoclonal antibodies specific for the immunodominant disulfide region (IDR) in the ectodomain of gp41 [182] [183] [184] , whereas one study also included A32 181 the canonical monoclonal antibody that defines the A32-subregion of Epitope Cluster A. 157, 160, 162, 174, 175 The first two studies showed that monoclonal antibodies specific for the IDR of gp41 afforded postinfection control of viremia after high-dose SHIV challenges. 33, 37 The third study 181 showed that both the monoclonal antibody specific for the IDR of gp41 and A32 significantly reduced the number transmitted viral variants, although there was no postinfection control of viremia.
We have suggested elsewhere that postinfection control and sterilizing protection are a continuum in passive immunization studies using high-dose SHIV challenges that is affected dramatically by antibody concentration. 11, [185] [186] [187] On the basis of these considerations, we propose that the differences between neutralizing and non-neutralizing antibodies to protect against HIV-1 are quantitative rather than qualitative. This hypothesis is consistent with the patterns of protection observed using the FLSC immunogen in high-dose SHIV challenges, 132 where only postinfection control was observed, compared with repeat, low-dose SHIV/SIV challenges where sterilizing protection was observed, 141 in all cases, protection correlated with CD4i antibody specificity and ADCC.
In summary, these studies suggest that using high-dose SHIV/ SIV challenge studies runs the risk of "throwing the baby out with the bathwater" as they appear to underestimate quantitative differences in the dynamic range of protection. This hypothesis can be tested in repeat, low-dose challenge studies that use SHIV inocula in the range of 10 5 to 10 6 copies per challenge, which more closely approximates the likely per exposure of HIV-1 inoculum of HIV-1 in at risk populations. 145 These studies are sorely needed as the bulk of the immunization literature cited above for both NHP and humans strongly suggest that vaccine elicited non-neutralizing antibodies should protect against inocula that are closer to those in natural infection. 145 If this hypothesis is correct, the choice of epitopes to be targeted is critical.
| ANTIBODY-MEDIATED PROTECTION AGAINST HIV-1: IDENTIFICATION OF POTENTIAL NON-SURVIVOR EPITOPES
Above we argued that neutralizing antibodies recognize "survivor" epitopes that can accommodate continual cycles of neutralization and escape and raised the possibility for the existence of "non-survivor" epitopes for which any mutation to escape an antibody results in a non-functional Env trimer. Thus far, it appears that all neutralizing epitopes can escape, though it is likely that some escapes will have decreased replication/transmission fitness. Escape is also possible for weakly or non-neutralizing anti-V2 antibodies that are a COR in RV144. 172 These antibodies do not neutralize Tier-2 viruses and only narrowly neutralize Tier-1 viruses, so it is unlikely that neutralization played a role in escape. In contrast, antibodies specific for this epitope region mediate potent ADCC and there is no reason to think that "survivor" epitopes are only impacted by neutralizing antibodies. The key point here is that these epitopes are in a highly variable region where was determined by residues at 169 and 181 in RV144. 172 In contrast, NHP vaccination studies using the FLSC immunogen 132, 139, 141 as well as RV144 168, 170 suggest that Epitope Cluster-A is also a target of potentially protective non-neutralizing antibodies raising the question of whether these epitopes are survivors or non-survivors.
| Are epitopes in the A32-subregion of Epitope Cluster A non-survivors?
It has been known for many years that the A32 epitope is expressed across HIV-1 clades 188 and that most HIV-1 infected individuals mount antibody responses to this epitope 173, 189 as did RV144 vaccinees.
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We now have a detailed structural picture of the A32-subregion of Epitope Cluster A that permits the search for potential escape mutations by probing sequence databases from infection cohorts. Epitope
Cluster A is comprised of three sub-regions, one that is recognized by A32, a second that is recognized by monoclonal antibody C11, and a third that overlaps both regions. 157, 160, 162, 175 Monoclonal antibodies A32 and C11 recognize distinct but proximal epitopes that map to the gp41-interactive surface of gp120. 157, 160, 162, 174, 175, 187 For this reason, Epitope Cluster A is buried in native Env trimers on virions [190] [191] [192] or the surfaces of HIV-1 infected cells but become antibody accessible after binding to cell surface CD4. 157, [160] [161] [162] 173, 193 Once exposed, Epitope Cluster A becomes a very potent ADCC target. 157, 173, 193 Because Epitope Cluster-A becomes an ADCC target only upon CD4-induced conformational rearrangement, the window of time where a target cell can be eliminated is relatively short. Epitope Cluster A is exposed during viral entry for at least several hours 194, 195 where it is a potent ADCC target. 157 Epitope Cluster A is also exposed on productively infected cells where it remains a potent ADCC target until CD4 is down-regulated by Nef and Vpu. 16, 189, 193, 196, 197 These studies strongly suggest that Nef and Vpu have evolved, in part, to reduce the exposure of Epitope Cluster A during viral budding. It is interesting to note that the ability of Nef to down-regulate CD4 is allele dependent and that Elite Controllers often have defective alleles and increased exposure of Epitope Cluster A for ADCC attack. 197 The mapping of Epitope Cluster A to an Env structure that is indispensable for viral entry and the evolution of a mechanism to reduce its exposure on HIV-1 infected cells raises the possibility that these epitopes are "nonsurvivors" for which escape is impossible or at least highly improbable.
This question is addressed using the epitope footprint of the A32-subregion of Epitope Cluster A determined recently at the atomic level. 16, [160] [161] [162] The A32-subregion maps to the highly conserved C1 region involving residues between 50 and 115 as well as a highly conserved segment in the C2 region between residues 217 and 246. Figure 2 shows the epitope footprint of the A32-subregion derived from ten independent co-crystal structures for A32 and the A32-like monoclonal antibodies, N12-i2, 2.2c, N60-i3, and JR4. 160, 162, 175 The A32-subregion epitopes are discontinuous and include the α-0 and α-2 helices and adjacent residues in C1 as well as a short segment of the C2 region, comprising part of the gp41 docking site in the Env trimer.
The epitope footprint is displayed on the surface of a gp120-CD4 complex that mimics FLSC [PDB:3JZO (198) ] with gp120 regions colored according to protein sequence conservation determined using the Los Alamos HIV Sequence Database (www.hiv.lanl.gov). The most coloring scheme ranges from most conserved (blue) to least conserved (red). The A32-subregion of Epitope Cluster-A is very highly conserved, which is also indicated by a "logo" plot in Figure 3 where the contact residues are in rectangles (depicted for only C1 residues). The high conservation of the A32-subregion and the data above showing that it is a target of potentially protective antibodies strongly suggest that it is comprised of non-survivor epitopes. This is supported by the lack of escape in the A32-subregion in the RV144 trial 172 despite the clear presence of antibody responses to this region in vaccines that have been implicated in protection. 168, 170, 176 Further, there was no escape in the A32-subregion in the NHP passive immunization study where A32 significantly reduced the number of transmitted variants of a high-dose SHIV162p3 challenge. 176 As pointed out above, ADCC associated escape has been reported for several regions of gp120, including the C1 region using F I G U R E 2 Depiction of the relative sequence variability on a model of CD4-triggered gp120. Blue represents the highest protein sequence conservation, whereas red represents the highest protein sequence variability a synthetic peptide approach. 199 In that study, the ADCC associated escape was at non-contact residues for antibodies that recognize the A32-subregion. Notably, the A32-subregion epitopes are discontinuous and involve two critical cysteine residues in the C1 region and one critical cysteine in the C2 region (not shown in Figure 3 ) all of which are completely conserved among HIV-1 isolates, 160, 162, 175 which might be a key factor in preventing epitope escape. The marked conservation of the A32-subregion across HIV-1 isolates raises the question of its relationship with the I33, A55, K64, N88 T/F signature motif. As pointed out in, 57 the I33 and N88 residues are distal to this sub-region.
Although A55 and K64 are not contact residues for A32-like antibodies, these residues interact with the residues comprising the A32-subregion and likely stabilize its structure. The high conservation of the A55 and K64 residues as well as the residues comprising the A32-subregion suggests that this subregion is comprised of non-survivor epitopes.
Future studies analyzing the relationships between the appearance of antibodies to A32-subregion epitopes and the evolution of sequence changes are required to test the non-survivor hypothesis.
| CONCLUSIONS
The discussion above frames the protective epitope diversity prob- shown that non-neutralizing anti-gp41 antibodies correlated with protection against a high-dose SIV challenge in live attenuated vaccine model. 143, 144 The ability of an anti-gp41 monoclonal antibody to the PID to decrease the number of T/F variants in a high-dose SHIV passive immunization study further supports this possibility.
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Further, the identification of the highly conserved fusion sequence in gp41 as an element of an epitope recognized by a new broadly neutralizing antibody is also a possible non-survivor neutralizing epitope candidate. 200 Further exploration of these concepts will require refinements of the relatively simple models and systems now being from The Bill and Melinda Gates Foundation. I was also supported by NIH grants P01 AI120756-01, P01AI124912, and R01AI116274.
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F I G U R E 3
Logo plots for the per-residue protein sequence variation in the C1 region. The rectangles represent contact residues for the A32-subregion of Epitope Cluster A. For brevity, the C2 contact residues for the A32-subregion are not shown but they are equally conserved as those of the C1 region
